0001185185-26-000633 Sample Contracts
Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 20th, 2026 • Vogenx, Inc. • Pharmaceutical preparations
This EXCLUSIVE LICENSE AGREEMENT becomes effective as of 21st day of December, 2021 (the “Effective Date”) by and between Kissei Pharmaceutical Co., Ltd., a corporation duly organized and existing under the laws of Japan and having its registered office at 19-48, Yoshino, Matsumoto-City, Nagano- Prefecture, Japan (“Kissei”) and Vogenx, Inc., a corporation duly organized and existing under the laws of North Carolina, and having its principal place of business at 3200 East Hwy 54, Suite 100, Research Triangle Park, NC 27709 United States (“Vogenx”). Each of Kissei and Vogenx is referred to herein as a “Party” and collectively, as the “Parties.”
VOGENX, INC. CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note • February 20th, 2026 • Vogenx, Inc. • Pharmaceutical preparations • Delaware
This Note is issued as part of a series of similar convertible promissory notes (collectively, the “Notes”) pursuant to the terms of that certain Convertible Promissory Note Purchase Agreement, dated as of [__________ __, ______], by and among the Company and the persons and entities listed on the Schedule of Purchasers attached to the Agreement as Exhibit B, as may be amended from time to time (the “Agreement”). Capitalized terms used herein without definition shall have the meanings given to such terms in the Agreement.
COMMON STOCK PURCHASE WARRANT VOGENX, INC.Common Stock Purchase Warrant • February 20th, 2026 • Vogenx, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Vogenx, Inc., a Delaware corporation (the “Company”), up to [________] shares (the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).